spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Vetter further expands its Development Service with new site in Austria

Vetter Pharma International GmbH


  • CDMO addressing growing customer demand
  • Investment in additional clinical filling options in Europe
  • Planned ‘go live’ in 2021

Ravensburg, Germany and Rankweil, Austria, July 8, 2020 – With biopharmaceutical development heavily focused on specialized therapeutics, drug sponsors are increasingly turning to expert outsourcing partners to meet growing demand for complex fill and finish solutions. Vetter, a leading global Contract Development and Manufacturing Organization (CDMO) is further investing in additional capacity to meet that growing global demand with the purchase of a clinical manufacturing site located in Austria.

As the healthcare environment continues to evolve, the global shift towards specialized medications, complex molecules, and smaller batch sizes has rapidly expanded the role of the manufacturing partner. “An ever-growing number of pharmaceutical and biotech companies are seeking manufacturing partners who provide comprehensive clinical manufacturing resources as well as customized and product specific support with their development strategy,“ says Senator h.c. Udo J. Vetter, Chairman of the Advisory Board. “The new site expands our European footprint and can be seen as counterpart to our existing US clinical manufacturing site near Chicago.”

The production site was purchased along with its existing inventory including a vial filling line and a freeze dryer for liquid and lyophilized products as well as material preparation and laboratory equipment. Thomas Otto, Managing Director, Vetter explains: ”With the additional site we will further support our capability for early clinical development in Phase I and Phase II. Over the coming months the facility will be evaluated and modified to the extensive Vetter quality and process standards in aseptic fill and finish for injection systems. Only an hour’s drive from Vetter’s headquarters in Ravensburg, Germany, the new site is well-positioned for a successful integration into our existing clinical operations.”

Vetter Development Service Rankweil (VDS-R) plans call for the start of operations in the second half of 2021.

Find the Vetter press kit and more background information here.

About Vetter
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. Currently employing 5,000 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5 88212 Ravensburg Germany
Phone: +49 (0)751-3700-3729
phone +49 751 3700 0
email info@vetter-pharma.com
web www.vetter-pharma.com
email Eywiesenstraße 5, 88212 Ravensburg, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Byondis’ Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL™ in Early-Stage Breast Cancer

Byondis B.V. (formerly Synthon Biopharmaceuticals) today announced that Quantum Leap Healthcare Collaborative™ (Quantum Leap) selected the company’s investigational antibody-drug conjugate (ADC) SYD985 ([vic-]trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.
More info >>


White Papers

Bonfiglioli Engineering Headspace Gas Analysis Systems for Parenteral Manufacturing Processes: One Step Beyond Product Quality and Patient Safety

Bonfiglioli Engineering

This white paper presents the innovative solutions that Bonfiglioli Engineering has been developing in the field of HGA and their significant advantages over other existing systems.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement